November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Dr. Edward Kim on Indicating Patient Populations With Biomarkers in NSCLC
March 29th 2016Edward Kim, MD, chair of the department of Solid Tumor Oncology, Levine Cancer Institute, discusses the further work that needs to be done when indicating patient populations with certain biomarkers in non-small cell lung cancer (NSCLC).
Watch
Dr. Sarah Goldberg on Further Immunotherapy Trials in Non-Small Cell Lung Cancer
March 29th 2016Sarah Goldberg, MD, MPH, assistant professor of Medicine and Medical Oncology, Yale Cancer Center, discusses coming trials looking at immunotherapy beyond the second-line setting in non-small cell lung cancer (NSCLC).
Watch
Everolimus Receives FDA Approval for GI, Lung NETs
February 27th 2016Everolimus (Afinitor) has received FDA approval for adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal (GI) or lung neuroendocrine tumors (NET), based on findings from the phase III RADIANT-4 trial.
Read More
Phase III Trial of Bavituximab in NSCLC Halted After Futility Analysis
February 27th 2016In the study, the bavituximab combination showed OS data similar to expectations while patients in the docetaxel-alone arm "dramatically outperformed OS expectations," according to Peregrine Pharmaceuticals.
Read More
Durvalumab/Tremelimumab Shows Efficacy in NSCLC
February 16th 2016Patients with advanced non-small cell lung cancer receiving the combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the anti-CTLA-4 agent tremelimumab had a response rate of 23%, according to phase Ib data from Study 006.
Read More
FDA Requests ODAC Meeting for Rociletinib Following Updated Data
February 15th 2016The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) advisory hearing for April 12 to review the new drug application for rociletinib, a treatment for metastatic EGFR T790-mutated non-small cell lung cancer.
Read More
Dr. Eric Lim on the Diagnosis of Lung Cancer in Non-Smoker Patients
January 28th 2016Eric Lim, MD, consultant thoracic surgeon, Royal Brompton Hospital, Senior lecturer in thoracic surgery and reader, Imperial College London, discusses the decline in smoking not correlating to the current amount of lung cancer diagnoses.
Watch
Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
January 18th 2016Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Watch
Biopsy Requirements Impede Enrollment in Clinical Trials for Advanced NSCLC
January 18th 2016A study analysis tackles the ethical debate surrounding the impact of the increasing requirement for research biopsies on the participation of patients with advanced non-small lung cancer in clinical trials.
Read More
Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients
January 18th 2016Marianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.
Watch
FDA Approves Non-Alcohol Formulation of Docetaxel for Multiple Cancer Types
December 29th 2015The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Read More
Decision on Rociletinib for NSCLC Delayed by FDA
December 17th 2015The review period for rociletinib for EGFR T790M-positive non-small cell lung cancer (NSCLC) has been extended by the FDA by 3 months. The extension allows ample time to review additional data submitted by the drug's developer, Clovis Oncology.
Read More